Patients with febrile neutropaenia (FN) can be stratified according to their risk of significant complications, allowing reduced intensity therapy for low risk (LR) episodes. Serious events are very rare in low risk episodes making randomised trials difficult. Introduction of new evidence-based guidelines followed by re-auditing of the outcome is an alternative strategy.
|Number of pages||7|
|Journal||European journal of cancer (Oxford, England : 1990)|
|Publication status||Published - 2009|